ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.Journal of the National Cancer Institute · 2025Pooled it
- Role of Radiotherapy After Breast-Conserving Surgery in T1-2N0M0 Luminal (HR+/HER2-) Breast Cancer Stratified by Tumor Quadrant Location.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Impact of Omission of Sentinel Lymph Node Surgery on Radiation Treatment in Patients Age 50 and Older with Breast Cancer Treated with Lumpectomy: A Single-Institution Retrospective Review.Annals of surgical oncology · 2026Article
- Patient Selection for Partial Breast Irradiation in the Era of Sentinel Lymph Node Biopsy Omission: A Narrative Review.Cancers · 2026Review
- Omission of Sentinel Lymph Node Biopsy Among Women Aged 50 to 70 With Early-Stage Breast Cancer: Applying an Updated ASCO Guideline to a Real-World Population.Practical radiation oncology · 2026Article
- Single fraction based-partial breast irradiation: 10-year results of the SiFEBI phase 2 prospective trial.Clinical and translational radiation oncology · 2026Article
- ASO Author Reflections: Onward with Sentinel Lymph Node Omission: Implications of SOUND and INSEMA Trials for Mastectomy Patients.Annals of surgical oncology · 2026Article
- Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early-Stage Node-Negative HR+/HER2- Breast Cancer Undergoing Mastectomy.Annals of surgical oncology · 2026Article
- Headwinds in Breast Cancer Research: The Case for Pragmatic Radiotherapy De-escalation Studies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Personalized recurrence risk prediction in early-stage breast cancer through an integrative mathematical model based on MammaPrint®, radiotherapy, phenotype, and clinicopathological factors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patients.Breast cancer research : BCR · 2026Article
- Review
- Beyond surface dose: subcutaneous dose escalation underlies TomoTherapy's skin toxicity in breast radiotherapy.Frontiers in oncology · 2026Article
- The 19th St. Gallen international breast cancer conference 'primary therapy of patients with early breast cancer. Evidence, controversies, consensus': key moments and breakthroughs.Ecancermedicalscience · 2026Article
- The Canadian Breast Cancer Symposium 2025: Meeting Report.Current oncology (Toronto, Ont.) · 2025Article
- Financial De-Escalation in T1 Breast Cancers With the Low Magee Equation: An Experience From A Single Institution Without Genomic Testing.European journal of breast health · 2025Article
- Radiotherapy omission in low-risk hormone receptor-positive breast cancer: insights from a Korean single-center cohort.Radiation oncology journal · 2025Article
- Radiomics Analysis of QUS Spectral Parametric Images for Predicting the Risk of Breast Cancer Recurrence.Cancers · 2025Article
- Omitting radiotherapy in LUMINA-like breast cancer after breast conserving surgery: 10-year results of a population-based cohort study.The oncologist · 2025Article
- Internal mammary node failure in invasive breast cancer patients who received post-operative radiotherapy without prophylactic internal mammary node irradiation.Breast cancer (Tokyo, Japan) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 16 institutions in 1 country.
Funding
Abstract
purposeMultiple studies have shown a low risk of ipsilateral breast events (IBEs) or other recurrences for selected patients age 65-70 years or older with stage I breast cancers treated with breast-conserving surgery (BCS) and endocrine therapy (ET) without adjuvant radiotherapy. We sought to evaluate whether younger postmenopausal patients could also be successfully treated without radiation therapy, adding a genomic assay to classic selection factors.
methodsPostmenopausal patients age 50-69 years with pT1N0 unifocal invasive breast cancer with margins ≥2 mm after BCS whose tumors were estrogen receptor-positive, progesterone receptor-positive, and human epidermal growth factor receptor 2-negative with Oncotype DX 21-gene recurrence score ≤18 were prospectively enrolled in a single-arm trial of radiotherapy omission if they consented to take at least 5 years of ET. The primary end point was the rate of locoregional recurrence 5 years after BCS.
resultsBetween June 2015 and October 2018, 200 eligible patients were enrolled. Among the 186 patients with clinical follow-up of at least 56 months, overall and breast cancer-specific survival rates at 5 years were both 100%. The 5-year freedom from any recurrence was 99% (95% CI, 96 to 100). Crude rates of IBEs for the entire follow-up period for patients age 50-59 years and age 60-69 years were 3.3% (2/60) and 3.6% (5/140), respectively; crude rates of overall recurrence were 5.0% (3/60) and 3.6% (5/140), respectively.
conclusionThis trial achieved a very low risk of recurrence using a genomic assay in combination with classic clinical and biologic features for treatment selection, including postmenopausal patients younger than 60 years. Long-term follow-up of this trial and others will help determine whether the option of avoiding initial radiotherapy can be offered to a broader group of women than current guidelines recommend.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.